CAS: 79778-41-9; (6-Amino-1-Hydroxyhexane-1,1-Diyl)Bis(Phosphonic Acid)

该化合物是一种主要用于治疗骨骼疾病,特别是骨质疏松症和Pecet病的双磷化合物,它通过抑制骨质疏松症的中流骨再吸附作用,从而有助于保持骨密度和强度; 肾上腺素的化学结构具有中磷原子质,它与两种氢氧乙基基基组和两种磷酸酯组结合,有助于其生物活动; 它通常是静脉注射,体内的半衰期相对较长,可以比其他一些二磷酸酯少下剂量; 肾上腺素在减少骨质疏松症患者骨折风险方面的效力是众所周知的,并且还被用于管理与转移性癌症有关的骨痛; 常见的副作用可能包括胃肠紊乱,在少数情况下,下巴的骨质内腺囊炎. 总的来说, nirdronate是各种与骨质有关条件管理中的一个重要治疗选择.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号60-32-2 6-氨基己酸 | CAS号10294-56-1 亚磷酸 | CAS号4443-26-9 6-(1,3-二氧代异吲哚-2-基)己酸 | CAS号31968-60-2 6-phthalimidohe...

合成工艺路线路线简述

  • 合成目标产物 Neridronate Sodium Hydrate 主要起始原料 6-Aminocaproic Acid
  • 60-32-2 = 79778-41-9
    反应条件:1.1 Reagents: Methanesulfonic Acid,Phosphorus Trichloride,Phosphonic Acid; 65 °C; 16 - 20 H,65 - 70 °C1.2 Solvents: Water; Cooled; 5 H,Reflux
    标题:Systematic Study Of The Physicochemical Properties Of A Homologous Series Of Aminobisphosphonates
    作者:Alanne,Aino-Liisa; Et Al
    参考文献:Molecules 日期:2012 卷标:17 页码:10928-10945]

    60-32-2 = 79778-41-9
    反应条件:1.1 Reagents: Methanesulfonic Acid,Phosphorus Trichloride; 15 Min,Rt; 4 - 6 H,80 - 85 °C; 85 °C -> Rt1.2 Reagents: Water; 4 H,105 °C; Cooled1.3 Reagents: Sodium Hydroxide Solvents: Water; Ph 6 - 7,Cooled
    标题:Biocompatible Organic Coatings Based On Bisphosphonic Acid Rgd-Derivatives For Peo-Modified Titanium Implants
    作者:Parfenova,Lyudmila V.; Et Al
    参考文献:Molecules 日期:2020 卷标:25(1)]

    60-32-2 = 79778-41-9
    反应条件:1.1 Reagents: Methanesulfonic Acid,Phosphorus Trichloride,Phosphonic Acid; Overnight,65 °C1.2 Reagents: Water; 5 H,Reflux1.3 Reagents: Sodium Hydroxide Solvents: Water; Rt
    标题:Synthesis And Biological Evaluation Of New Bisphosphonate-Dextran Conjugates Targeting Breast Primary Tumor
    作者:Migianu-Griffoni,Evelyne; Et Al
    参考文献:Bioconjugate Chemistry 日期:2014 卷标:25(2) 页码:224-230]

    948317-80-4 = 79778-41-9
    反应条件:1.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Water; 0 °C; 0.5 H,Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 1
    标题:Syntheses Of Phosphonic Esters Of Alendronate,Pamidronate And Neridronate
    作者:Guenin,Erwann; Et Al
    参考文献:European Journal Of Organic Chemistry 日期:2007 卷标:(20) 页码:3380-3391]

    31968-60-2 = 79778-41-9
    反应条件:1.1 Reagents: Silanol,1,1,1-Trimethyl-,1,1′,1′′-Phosphite; -5 °C; 4 H,Rt1.2 Reagents: Methanol2.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Water; 0 °C; 0.5 H,Rt2.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 1
    标题:Syntheses Of Phosphonic Esters Of Alendronate,Pamidronate And Neridronate
    作者:Guenin,Erwann; Et Al
    参考文献:European Journal Of Organic Chemistry 日期:2007 卷标:(20) 页码:3380-3391]

    4443-26-9 = 79778-41-9
    反应条件:1.1 Reagents: Oxalyl Chloride Solvents: Dichloromethane; 6 H,Reflux2.1 Reagents: Silanol,1,1,1-Trimethyl-,1,1′,1′′-Phosphite; -5 °C; 4 H,Rt2.2 Reagents: Methanol3.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Water; 0 °C; 0.5 H,Rt3.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 1
    标题:Syntheses Of Phosphonic Esters Of Alendronate,Pamidronate And Neridronate
    作者:Guenin,Erwann; Et Al
    参考文献:European Journal Of Organic Chemistry 日期:2007 卷标:(20) 页码:3380-3391]

    60-32-2 = 79778-41-9
    反应条件:1.1 6 H,170 °C2.1 Reagents: Oxalyl Chloride Solvents: Dichloromethane; 6 H,Reflux3.1 Reagents: Silanol,1,1,1-Trimethyl-,1,1′,1′′-Phosphite; -5 °C; 4 H,Rt3.2 Reagents: Methanol4.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Water; 0 °C; 0.5 H,Rt4.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 1
    标题:Syntheses Of Phosphonic Esters Of Alendronate,Pamidronate And Neridronate
    作者:Guenin,Erwann; Et Al
    参考文献:European Journal Of Organic Chemistry 日期:2007 卷标:(20) 页码:3380-3391

海关参考信息

专利信息


专利号:US-9353057-B2
优先权日:2003-12-30
标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
权利人:XENOPORT INC
摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

专利号:EP-1566177-A1
优先权日:2004-02-23
标 题:The use of bisphosphonates for treating skin by stimulating of collagen synthesis
发明人:KIM JIN; YOOK JONG IN; KIM NAM HEE; RYU JU KYOUNG
权利人:TIGEN BIOTECH CO LTD
摘要:The present invention relates to a novel use of bisphosphonate, and morenparticularly to a composition for increasing collagen synthesis comprisingnbisphosphonate as an active ingredient, as well as the use thereof. The inventivencomposition comprising the bisphosphonate promotes collagen synthesis, and thus, whennit is applied to the skin, it reduces wrinkles of the skin and makes the skin elastic. Fornthis reason, the inventive composition will be useful as cosmetics for the prevention ornimprovement of skin aging or a wound-healing agent. Furthermore, the inventivencomposition can remarkably increase the collagen synthesis of fibroblasts in vitro , andnthus, can be effectively used in the production of products containing collagen.

专利号:US-8734846-B2
优先权日:2008-06-16
标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
发明人:ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS
权利人:BIND BIOSCIENCES INC
摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

专利号:US-8017776-B2
优先权日:2003-07-15
标题 :Methods for synthesis of acyloxyalkyl compounds
发明人:BHAT LAXMINARAYAN; GALLOP MARK A
权利人:XENOPORT INC
摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

专利号:US-2015158809-A9
优先权日:2013-02-26
标 题 :Method of making 1-(acyloxy)-alkyl carbamate compounds
发明人:WANG HUAN; LIU PENG; DAI QUNYING; YIN HAO; RAILLARD STEPHEN P
权利人:XENOPORT INC
摘要:Methods of preparing carbamate prodrugs of amine-containing drugs are provided. Carbonates useful in the synthesis of the carbamate prodrugs are also provided.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Varenna M, Zucchi F, Failoni S, Becciolini A, Berruto M. Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study. Rheumatology (Oxford). 2015 Oct;54(10):1826-32. doi: 10.1093/rheumatology/kev123. Epub 2015 May 20. doi: 10.1038/pr.2014.20. Epub 2014 Feb 11. doi: 10.1093/rheumatology/ket321. Epub 2013 Sep 24. doi: 10.1093/rheumatology/kes312. Epub 2012 Nov 30. doi: 10.3390/molecules170910928. doi: 10.1111/j.1365-2141.2012.09152.x. Epub 2012 May 10. doi: 10.1016/j.bone.2011.11.028. Epub 2011 Dec 10. doi: 10.1007/s00774-011-0331-3. Epub 2011 Nov 8. doi: 10.1159/000331128. Epub 2011 Sep 27. doi: 10.1007/s00223-011-9489-x. Epub 2011 May 13. doi: 10.1002/jbmr.237. doi: 10.1016/j.ejpb.2010.05.013. Epub 2010 Jun 8. doi: 10.3899/jrheum.091016. doi: 10.1016/j.biopha.2009.06.014. Epub 2009 Oct 23. doi: 10.1007/s10637-009-9325-6. Epub 2009 Oct 2. doi: 10.1517/17425250903029190. Review. doi: 10.1016/j.ijpharm.2009.09.011. Epub 2009 Sep 11. Review.

合成参考文献


参考文献:10.1023/a:1006271332400
摘要:Ingram GC, Magnard JL, Vergne P, Dumas C, Rogowsky PM. ZmOCL1, an HDGL2 family homeobox gene, is expressed in the outer cell layer throughout maize development. Plant Mol Biol. 1999 May;40(2):343–54. doi: 10.1023/a:1006271332400.
参考文献:10.1007/s12519-020-00378-w
摘要:Sydlik C, Dürr HR, Pozza SB, Weißenbacher C, Roeb J, Schmidt H. Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention World Journal of Pediatrics. 2020 Aug 10;16(5):520–7. doi: 10.1007/s12519-020-00378-w.
参考文献:10.1186/s40348-020-00101-9
摘要:Etich J, Leßmeier L, Rehberg M, Sill H, Zaucke F, Netzer C, Semler O. Osteogenesis imperfecta—pathophysiology and therapeutic options. Molecular and Cellular Pediatrics. 2020 Aug 14;7(1):9. doi: 10.1186/s40348-020-00101-9.
参考文献:10.1021/jm0303709
摘要:Sanders JM, Ghosh S, Chan JM, Meints G, Wang H, Raker AM, Song Y, Colantino A, Burzynska A, Kafarski P, Morita CT, Oldfield E. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem. 2004 Jan 15;47(2):375–84. doi: 10.1021/jm0303709.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知